Picture loading failed.

Pre-Made Vobarilizumab biosimilar, Bispecific Single Domains (VH-VH'), Anti-IL6R;ALB Antibody: Anti-CD126/HIES5/IL-1Ra/IL-6R/IL-6R-1/IL-6RA/IL6Q/IL6QTL/IL6RA/IL6RQ/gp80;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vobarilizumab (INN; development code ALX0061) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-625-1mg 1mg Inquiry
GMP-Bios-ab-625-10mg 10mg Inquiry
GMP-Bios-ab-625-100mg 100mg Inquiry
GMP-Bios-ab-625-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Vobarilizumab biosimilar, Bispecific Single Domains (VH-VH'), Anti-IL6R;ALB Antibody: Anti-CD126/HIES5/IL-1Ra/IL-6R/IL-6R-1/IL-6RA/IL6Q/IL6QTL/IL6RA/IL6RQ/gp80;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody
INN Name Vobarilizumab
TargetIL6R;ALB
FormatBispecific Single Domains (VH-VH')
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
VD LCna
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2015
Year Recommended2016
CompaniesAblynx
Conditions Approvedna
Conditions Activena
Conditions Discontinuedna
Development TechNanobody Technology